Vividion, Roche partner for small-molecule drug discovery

By The Science Advisory Board staff writers

May 19, 2020 -- Biotechnology company Vividion Therapeutics has signed an exclusive worldwide option and license agreement with Roche.

Under the deal, Vividion's proteomics screening platform and small-molecule library will be utilized to target novel E3 ligases, as well as a range of oncology and immunology therapeutic targets.

Roche will have the exclusive right to license resulting compounds at different stages of development. Vividion will be responsible for early drug discovery and preclinical development for selected programs, according to the firm. For some of the programs, Vividion has the right to conduct clinical development up to a proof of concept, with the option to share development costs and split U.S. profits and losses with Roche.

Vividion will receive an up-front payment of $135 million, with the potential to receive payments potentially worth billions of dollars in the future for achieving preclinical, development, and commercial milestones, as well as from royalties on sales of commercialized products.

Roche becomes founding partner of biotech accelerator
Roche has become a founding partner in the second phase of development of BaseLaunch, a Basel, Switzerland-based incubator and accelerator that helps...
Proteomics provides insights into SARS-CoV-2 infection, potential therapies
Scientists tested a series of compounds for blocking the replication of SARS-CoV-2 using a novel proteomics approach. The method, which helped identify...
Arrakis Therapeutics partners with Roche
Biopharmaceutical firm Arrakis Therapeutics has inked a license agreement with Roche to collaborate on research of Roche's RNA-targeted small-molecule...
Supercomputer reveals potential compounds against coronavirus
Researchers from the U.S. Department of Energy's Oak Ridge National Laboratory have used the Summit supercomputer to identify 77 small-molecule drug compounds...
X-Chem, ALK partner on allergy drug discovery
X-Chem announced on February 5 a new drug discovery partnership with ALK-Abelló A/S. The collaboration will focus on the discovery of small-molecule...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter